vs
Side-by-side financial comparison of ARGENX SE (ARGX) and Cushman & Wakefield Ltd. (CWK). Click either name above to swap in a different company.
Cushman & Wakefield Ltd. is the larger business by last-quarter revenue ($2.5B vs $2.5B, roughly 1.0× ARGENX SE). On growth, ARGENX SE posted the faster year-over-year revenue change (83.2% vs 11.0%). ARGENX SE produced more free cash flow last quarter ($322.4M vs $-255.7M).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
Cushman & Wakefield Inc. is an American global commercial real estate and property management services firm. The company's corporate headquarters is located in Chicago, Illinois. It is named after co-founders J. Clydesdale Cushman and Bernard Wakefield.
ARGX vs CWK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $2.5B | $2.5B |
| Net Profit | $877.2M | — |
| Gross Margin | 89.5% | — |
| Operating Margin | 28.9% | 2.3% |
| Net Margin | 35.5% | — |
| Revenue YoY | 83.2% | 11.0% |
| Net Profit YoY | 1.3% | — |
| EPS (diluted) | $13.25 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $2.5B | ||
| Q4 25 | $2.5B | $2.9B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | $1.8B | $2.5B | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | $1.4B | $2.6B | ||
| Q3 24 | — | $2.3B | ||
| Q2 24 | $901.9M | $2.3B |
| Q1 26 | — | — | ||
| Q4 25 | $877.2M | $-22.4M | ||
| Q3 25 | — | $51.4M | ||
| Q2 25 | $414.8M | $57.3M | ||
| Q1 25 | — | $1.9M | ||
| Q4 24 | $865.6M | $112.9M | ||
| Q3 24 | — | $33.7M | ||
| Q2 24 | $-32.5M | $13.5M |
| Q1 26 | — | — | ||
| Q4 25 | 89.5% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 89.2% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 90.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 89.4% | — |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 28.9% | 6.1% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | 19.2% | 4.9% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | 8.7% | 6.6% | ||
| Q3 24 | — | 3.2% | ||
| Q2 24 | -15.4% | 3.1% |
| Q1 26 | — | — | ||
| Q4 25 | 35.5% | -0.8% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | 23.4% | 2.3% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 64.1% | 4.3% | ||
| Q3 24 | — | 1.4% | ||
| Q2 24 | -3.6% | 0.6% |
| Q1 26 | — | $-0.05 | ||
| Q4 25 | $13.25 | $-0.10 | ||
| Q3 25 | — | $0.22 | ||
| Q2 25 | $6.32 | $0.25 | ||
| Q1 25 | — | $0.01 | ||
| Q4 24 | $13.33 | $0.49 | ||
| Q3 24 | — | $0.14 | ||
| Q2 24 | $-0.55 | $0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.5B | $600.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3B | $2.0B |
| Total Assets | $8.7B | $7.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $600.6M | ||
| Q4 25 | $3.5B | $784.2M | ||
| Q3 25 | — | $634.4M | ||
| Q2 25 | $2.1B | $618.2M | ||
| Q1 25 | — | $623.2M | ||
| Q4 24 | $1.5B | $793.3M | ||
| Q3 24 | — | $775.4M | ||
| Q2 24 | $1.4B | $567.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.7B | ||
| Q3 25 | — | $2.8B | ||
| Q2 25 | — | $3.0B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $3.0B | ||
| Q3 24 | — | $3.1B | ||
| Q2 24 | $11.0M | $3.1B |
| Q1 26 | — | $2.0B | ||
| Q4 25 | $7.3B | $2.0B | ||
| Q3 25 | — | $2.0B | ||
| Q2 25 | $6.1B | $1.9B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | $5.5B | $1.8B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | $4.3B | $1.6B |
| Q1 26 | — | $7.6B | ||
| Q4 25 | $8.7B | $7.7B | ||
| Q3 25 | — | $7.7B | ||
| Q2 25 | $7.2B | $7.6B | ||
| Q1 25 | — | $7.4B | ||
| Q4 24 | $6.2B | $7.5B | ||
| Q3 24 | — | $7.5B | ||
| Q2 24 | $4.8B | $7.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.40× | ||
| Q3 25 | — | 1.45× | ||
| Q2 25 | — | 1.57× | ||
| Q1 25 | — | 1.70× | ||
| Q4 24 | — | 1.73× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | 0.00× | 1.91× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $323.3M | $-243.5M |
| Free Cash FlowOCF − Capex | $322.4M | $-255.7M |
| FCF MarginFCF / Revenue | 13.0% | -10.1% |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | 0.37× | — |
| TTM Free Cash FlowTrailing 4 quarters | $594.5M | $203.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-243.5M | ||
| Q4 25 | $323.3M | $257.3M | ||
| Q3 25 | — | $235.5M | ||
| Q2 25 | $361.8M | $9.6M | ||
| Q1 25 | — | $-162.0M | ||
| Q4 24 | $41.9M | $115.2M | ||
| Q3 24 | — | $196.1M | ||
| Q2 24 | $-124.7M | $21.8M |
| Q1 26 | — | $-255.7M | ||
| Q4 25 | $322.4M | $234.3M | ||
| Q3 25 | — | $225.0M | ||
| Q2 25 | $356.6M | $300.0K | ||
| Q1 25 | — | $-166.6M | ||
| Q4 24 | $40.9M | $105.9M | ||
| Q3 24 | — | $186.7M | ||
| Q2 24 | $-125.5M | $10.0M |
| Q1 26 | — | -10.1% | ||
| Q4 25 | 13.0% | 8.0% | ||
| Q3 25 | — | 8.6% | ||
| Q2 25 | 20.1% | 0.0% | ||
| Q1 25 | — | -7.3% | ||
| Q4 24 | 3.0% | 4.0% | ||
| Q3 24 | — | 8.0% | ||
| Q2 24 | -13.9% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.8% | ||
| Q3 25 | — | 0.4% | ||
| Q2 25 | 0.3% | 0.4% | ||
| Q1 25 | — | 0.2% | ||
| Q4 24 | 0.1% | 0.4% | ||
| Q3 24 | — | 0.4% | ||
| Q2 24 | 0.1% | 0.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | 4.58× | ||
| Q2 25 | 0.87× | 0.17× | ||
| Q1 25 | — | -85.26× | ||
| Q4 24 | 0.05× | 1.02× | ||
| Q3 24 | — | 5.82× | ||
| Q2 24 | — | 1.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ARGX
Segment breakdown not available.
CWK
| Services | $1.7B | 69% |
| Leasing | $497.7M | 20% |
| Capital markets | $181.6M | 7% |
| Valuation and other | $113.8M | 4% |
